L van Zuylen Selected Research

laniquidar (R101933)

5/2002	Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
7/2000	Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
4/2000	The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

L van Zuylen Research Topics

Disease

3	Neoplasms (Cancer) 04/2001 - 06/2000
1	Pain (Aches) 01/2016
1	Nausea 04/2013
1	Vomiting 04/2013
1	Sleepiness 05/2002
1	Fever (Fevers) 04/2000
1	Mucositis 04/2000

Drug/Important Bio-Agent (IBA)

3	laniquidar (R101933)IBA 05/2002 - 04/2000
2	Paclitaxel (Taxol)FDA LinkGeneric 04/2001 - 06/2000
2	Docetaxel (Taxotere)FDA Link 07/2000 - 04/2000
1	cyclopropapyrroloindoleIBA 01/2016
1	Opioid Analgesics (Opioids)IBA 04/2013
1	Haloperidol (Haldol)FDA LinkGeneric 04/2013
1	Midazolam (Versed)FDA LinkGeneric 04/2013
1	cremophor ELIBA 06/2000